ARHGEDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling

Heon Yung Gee,1 Pawaree Saisawat,2 Shazia Ashraf,1 Toby W. Hurd,3 Virginia Vega-Warner,2 Humphrey Fang,1 Bodo B. Beck,4 Olivier Gribouval,5,6 Weinbin Zhou,2 Katrina A. Diaz,2 Sivakumar Natarajan,2 Roger C. Wiggins,7 Svjetlana Lovric,1 Gil Chernin,2 Dominik S. Schoeb,2 Bugsu Ovunc,2 Yaacov Frishberg,8 Neveen A. Soliman,9,10 Hanan M. Fathy,11 Heike Goebel,12 Julia Hoefele,13 Lutz T. Weber,14 Jeffrey W. Innis,2,15 Christian Faul,16 Zhe Han,17 Joseph Washburn,18 Corinne Antignac,5,6 Shawn Levy,19 Edgar A. Otto,2 and Friedhelm Hildebrandt1,20

1Division of Nephrology, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. 2Department of Pediatrics and Communicable Diseases, University of Michigan, Ann Arbor, Michigan, USA. 3MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom. 4Institute of Human Genetics, University of Cologne, Cologne, Germany. 5INSERM Unité 983 and Service de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France. 6Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Paris, France. 7Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA. 8Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel. 9Department of Pediatrics, Kastr Al Ainy School of Medicine, Cairo University, Cairo, Egypt. 10Egyptian Group for Orphan Renal Diseases (EGORD), Cairo, Egypt. 11Pediatric Nephrology Unit, University of Alexandria, Alexandria, Egypt. 12Institute of Pathology, University Hospital Cologne, Cologne, Germany. 13Center for Human Genetics and Laboratory Medicine Dr. Klein, Dr. Rost and Colleagues, Martinsried, Germany. 14University Children’s Hospital, Ludwig-Maximilians Universität München, Munich, Germany. 15Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA. 16Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. 17Department of Internal Medicine — Molecular Medicine and Genetics, University of Michigan, Ann Arbor, Michigan, USA. 18University of Michigan Cancer Center, Ann Arbor, Michigan, USA. 19HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA. 20Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.

Nephrotic syndrome (NS) is divided into steroid-sensitive (SSNS) and -resistant (SRNS) variants. SRNS causes end-stage kidney disease, which cannot be cured. While the disease mechanisms of NS are not well understood, genetic mapping studies suggest a multitude of unknown single-gene causes. We combined homozygosity mapping with whole-exome resequencing and identified an ARHGEDIA mutation that causes SRNS. We demonstrated that ARHGEDIA is in a complex with RHO GTPases and is prominently expressed in podocytes of rat glomeruli. ARHGEDIA mutations (R120X and G173V) from individuals with SRNS abrogated interaction with RHO GTPases and increased active GTP-bound RAC1 and CDC42, but not RHOA, indicating that RAC1 and CDC42 are more relevant to the pathogenesis of this SRNS variant than RHOA. Moreover, the mutations enhanced migration of cultured human podocytes; however, enhanced migration was reversed by treatment with RAC1 inhibitors. The nephrotic phenotype was recapitulated in arhgdia-deficient zebrafish. RAC1 inhibitors were partially effective in ameliorating arhgdia-associated defects. These findings identify a single-gene cause of NS and reveal that RHO GTPase signaling is a pathogenic mediator of SRNS.

Introduction

Nephrotic syndrome (NS) is caused by malfunction of the kidney glomerular filter, resulting in proteinuria, hypoalbuminemia, and edema. NS is classified by its response to steroid treatment into steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) categories. SSNS represents one of the most frequent kidney diseases and constitutes 80% of all childhood NS. Histologically, it presents as minimal change nephrotic syndrome (MCNS). Very little is known about its primary causes, disease processes, or mechanisms of treatment. SRNS is mostly refractory to therapy and leads to end-stage kidney disease (ESKD) within a few years of onset, requiring renal replacement therapy for survival. It causes about 15% of all ESKD in children (1), is considered one of the most intractable kidney diseases, and has a 30% recurrence risk in renal transplants, leading again to ESKD. Histologically, SRNS presents as focal segmental glomerulosclerosis (FSGS) or as the early-onset developmental variant, diffuse mesangial sclerosis (DMS) (2). There is clinical overlap between SSNS and SRNS, as some individuals with SSNS and MCNS may later develop SRNS with FSGS histology.

The discovery of single-gene causes of SRNS has generated the first insights into its pathogenesis by revealing that the defective proteins are essential for glomerular podocyte function (3). Podocytes constitute the outer epithelial layer of the 3-layered capillaries in the glomerular filter, which also consists of the glomerular basement membrane (GBM) and the endothelial cell (EC) layer (4). Podocytes are neuron-like cells that extend multiple tubulin-based primary processes, which branch off actin-based foot processes. The foot processes interdigitate with those of neighboring podocytes and form between them the glomerular slit diaphragm, which is critical for the filtering process and the retention of pro-

Authorship note: Heon Yung Gee, Pawaree Saisawat, and Shazia Ashraf contributed equally to this work.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(8):3243–3253. doi:10.1172/JCI69134.
tein in the bloodstream. Integrin molecules in the “sole plate” of the foot processes tether the foot processes to the GBM. Loss of foot processes and slit membrane integrity causes glomerular protein leakage and NS. The products of single-gene causes of SRNS play a role in cell-cell signaling at the podocyte slit membrane (NPHS1, NPHS2, CD2AP, PTPRO/GLEPP1) (5–8) for regulation of the foot process actin network (ACTN4 and INF2) (9, 10) or in foot process-GBM interaction (LAMB2 and ITGA3) (11–14).

While the disease mechanisms of NS are still obscure, features of podocyte cell migration were recently implicated in its pathogenesis. In this concept, a sessile podocyte phenotype represents the physiologic mode, whereas a migratory phenotype represents the nephrotic mode (15). Actin remodeling by members of the RHO family of small GTPases (referred to hereafter as RHO GTPases) regulates the 2 modes, where active RHOA and increased actin remodeling are seen in the nephrotic state (16). Conversely, inactivation of RHO GTPases may cause proteinuria in animal models, e.g., in Cdc42–/– mice (17) as well as in transgenic mice that express a dominant-negative Rhoc mutant (18). Apparently, both increased and decreased RHO GTPase signaling interfere with the state of podocyte mobility, thus causing proteinuria (19). Furthermore, mutations in the non-muscle class I myosin MYO1E cause proteinuria in humans due to decreased podocyte migratory ability (20).

Many of the genes that cause NS, if mutated, act in a recessive mode (e.g., NPHS1, NPHS2, and PLCE1) (5, 6, 21). Because recessive single-gene mutations directly represent the primary cause of a genetic disease, gene identification offers a powerful approach toward revealing disease mechanisms. Since recessive mutations predominantly convey loss of function, recessive single-gene defects can be directly transferred into animal models to study the related disease mechanisms and to screen for small molecules as possible treatment modalities. However, no caus-
Table 1 ARHGDIA mutations in individuals with SRNS

<table>
<thead>
<tr>
<th>Family -sibling origin</th>
<th>Ethnic</th>
<th>Parental consanguinity</th>
<th>Causative gene identified</th>
<th>Nucleotide alteration(s)(^a,b) in coding sequence</th>
<th>Exon (segregation)</th>
<th>Continuous amino acid sequence conservation</th>
<th>Age at onset</th>
<th>NS variant (histology; at age)</th>
<th>Extrarenal manifestations</th>
</tr>
</thead>
<tbody>
<tr>
<td>-21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-21: SRNS, ESKD 2.4 yr, (DMS; 2.4 yr)</td>
<td></td>
</tr>
<tr>
<td>-22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 yr</td>
<td>-22: NS (no Bx)</td>
<td>-22: ND, died at 19 mo</td>
</tr>
<tr>
<td>-23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1 yr</td>
<td>-23: SRNS, ESKD 3 yr</td>
<td>-23: ID</td>
</tr>
<tr>
<td>A4578 Moroccan</td>
<td>Yes</td>
<td></td>
<td>ARHGDIA</td>
<td>c.358C&gt;T</td>
<td>p.R120X</td>
<td>4 (Hom, M, F)</td>
<td>14 d</td>
<td>CNS (DMS; 1 mo), ESKD 6 wk</td>
<td>ID, seizures, cortical blindness, died at 6 mo</td>
</tr>
</tbody>
</table>

\(^a\)All mutations were absent from greater than 78 healthy control individuals and from greater than 8,600 European controls on the EVS (http://evs.gs.washington.edu/EVS/). \(^b\)GenBank accession number for human ARHGDIA is NM_001185077.1; Bx, renal biopsy; Hom, homozygous in affected individual; CNS: congenital nephrotic syndrome; F, heterozygous mutation identified in father; ID, intellectual disability; M, heterozygous mutation identified in mother; ND, no data or DNA available; SNHL, sensorineural hearing loss.


delete gene is known for SSNS. Likewise, in more than 80% of all cases of SRNS, the molecular cause is unknown, and treatment options have yet to be discovered (22).

Although the onset of SRNS in the first year of life is mostly a single-gene disorder, i.e., more than two-thirds of cases are caused by a mutation in 1 of only 5 different disease genes (NPHS1, NPHS2, WT1, LAMB2, or PLCE1) (21, 23), genetic mapping data strongly suggest that there are a multitude of additional disease genes that cause SRNS later in life (24). The finding that some of the more recently identified recessive genetic causes of NS are exceedingly rare (LAMB2, refs. 12, 25; PLCE1, ref. 21; and COQ6, ref. 26) necessitates the ability to identify novel single-gene causes of NS in families with only a single affected individual. The new method of whole-exome resequencing (WER) theoretically offers a powerful approach to identifying genes in rare recessive diseases. However, its utility is hampered by the large number of genetic variants that are observed with WER in any given individual (27, 28). To overcome this limitation, we developed a strategy that a priori restricts the number of variants by combining WER (28) with homozygosity mapping (24). We applied this approach to families affected by SRNS or SSNS and identified a novel recessive, full-penetrance cause of SRNS. We generated direct evidence in humans that loss of function of ARHGDIA causes NS by interference with RHO GTPase signaling, thereby altering the podocyte migratory state. We recapitulated features of NS in a zebrafish model and demonstrated that RAC1 inhibitors mitigate the NS phenotypes. Our findings may have implications for the development of new therapeutic approaches to NS.

Results Mutations in ARHGDIA cause NS. We performed homozygosity mapping (HM) in a family (A1432) of Ashkenazi Jewish origin in whom 2 siblings had early-onset SRNS with renal histology of DMS. HM yielded 5 regions of homozygosity by descent as candidate regions for a recessive SRNS gene (Figure 1A) (24). Using WER, we detected in both siblings a homozygous missense mutation (c.518G>T; p.G173V) of ARHGDIA (RefSeq accession number NM_001185077.1) encoding the RHO GDP dissociation inhibitor α (Figure 1B and Table 1). The altered amino acid residue is conserved, including S. cerevisiae. When we examined 65 additional individuals with DMS and 350 individuals with SRNS, we detected a homozygous mutation (c.358C>T;p.R120X) in an infant (A4578-21) with congenital NS (Figure 1B and Table 1). This infant also exhibited renal histology of DMS (Figure 1C and Table 1). Both mutations were absent from more than 190 ethnically matched healthy control individuals and from more than 8,600 European controls in the Exome Variant Server (EVS) (http://evs.gs.washington.edu/EVS/). The primary cellular function of ARHGDIA is to interact with RHO GTPases, including RHOA, RAC1, and CDC42, locking them into their cytosolic, inactive, GDP-bound states (29). Thus, ARHGDIA indirectly regulates actin cytoskeleton–dependent cellular functions. Depletion of Arhgdia was shown to cause early-onset NS in mice (30).

Arhgdia localizes to podocytes in glomeruli. Because most gene products that are defective in SRNS are located in glomerular podocytes, we examined adult rat kidney sections and found subcellular localization of ARHGDIA. Indeed, ARHGDIA is enriched in both differentiated and undifferentiated human podocytes (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI69134DS1). In glomeruli, ARHGDIA is prominently expressed in podocytes as identified by the expression of nuclear WT1 (Figure 2A). ARHGDIA partially colocalized with synaptopodin, which colocalizes with ARHGAP24 (31) and regulates RHOA signaling (Figure 2A) (32). ARHGDIA appeared to localize to the nucleus in some podocytes, and nuclear localization of ARHGDIA has been previously reported (33). ARHGDIA also colocalized with the phospholipase C ε1 (PLCε1) protein, which is defective in SRNS type 3 (21). ARHGDIA partially colo-
calized with PLC\(\varepsilon\)1 to podocyte cell bodies and primary processes (Figure 2B), suggesting a defect in podocyte function as central to the pathogenesis of \textit{ARHGDI}A mutations. Since \textit{ARHGDI}A is a regulator of \textit{RHO} GTPases (29), we examined its colocalization with the \textit{RHO} GTPases RHOA, RAC1, and CDC42. RHOA, RAC1, and CDC42 exhibited broad glomerular staining in podocyte cell bodies and processes (Figure 2C). \textit{ARHGDI}A partially colocalized with RHOA, RAC1, and CDC42 in proximal cell bodies and primary processes, whereas RHOA, RAC1, and CDC42 exhibited a broad glomerular staining pattern in podocyte cell bodies and processes. Our findings are congruent with the proposed regulatory role of \textit{RHO} GTPases in these podocyte structures (15, 19).

\textit{ARHGDI}A and \textit{RHO} small GTPases form a complex, and mutations abrogate interaction. To further elucidate the role of \textit{ARHGDI}A in the functioning of the \textit{RHO} small GTPases RAC1, CDC42, and RHOA in podocytes, we performed coimmunoprecipitation experiments of \textit{ARHGDI}A in rat renal glomerular lysates as an endogenous, disease-relevant source of podocyte proteins. We demonstrate that an anti-\textit{ARHGDI}A antibody coimmunoprecipitated with all 3 \textit{RHO} small GTPases, RHOA, RAC1, and CDC42 (Figure 2D), strongly suggesting that the pathogenesis of \textit{ARHGDI}A defects is related to \textit{RHO} small GTPase function.

We then performed coimmunoprecipitation studies in cultured human podocytes to examine whether the 2 \textit{ARHGDI}A mutants, which we identified in the family with SRNS, affect protein-protein interaction. Overexpression of the \textit{ARHGDI}A mutants (R120X and G173V) abrogated interaction with endogenous RHOA, RAC1, and CDC42. (Figure 3A and Supplemental Figure 2A). Comparable results were seen upon a GST pulldown assay in rat renal glomerular lysates (Supplemental Figure 2B).

\textit{ARHGDI}A mutations cause increased levels of active RAC1 and CDC42 and fail to regulate the podocyte migratory phenotype. As \textit{ARHGDI}A is known to regulate the inactive GDP-bound versus the active GTP-bound states of \textit{RHO} GTPases (29), we examined the effect of \textit{ARHGDI}A mutations on the active states of \textit{RHO} GTPases. We used purified PAK1 to assay the active GTP-bound states of RAC1 and CDC42 (Figure 3B) and used rhotekin to assay the active state of RHOA (Figure 3C). As expected, wild-type \textit{ARHGDI}A, when overexpressed in cultured human podocytes, decreased the GTP-bound forms of RAC1, CDC42, and RHOA. In contrast, overexpression of the truncating \textit{ARHGDI}A mutant (R120X) failed to decrease the active states of RAC1 and CDC42, and the missense mutant (G173V) only weakly decreased their active states.
Figure 3
Effects of disease-causing ARHGDA mutations on protein-protein interaction, RHO GTPase activity, and podocyte migration. (A) Interaction of wild-type ARHGDA and 2 mutants (p.R120X and p.G173V) with RHO GTPases. FLAG-tagged ARHGDA constructs were transfected into podocytes and were coimmunoprecipitated with endogenous RHO GTPases. Note that the R120X and G173V mutants abrogated interaction with RHOA, RAC1, and CDC42. (B) Active GTP-bound forms of RAC1 and CDC42 precipitated from podocytes expressing FLAG-ARHGDA (wild-type and mutants) using a GST-PAK1 (CRIB, CDC42, and RAC interactive binding domain) pulldown assay. Five percent input represents the controls for equal loading. Note that, compared with mock cells, podocytes expressing ARHGDA-WT exhibited a substantial decrease in active RAC1 and CDC42. This decrease was abrogated in the null mutant R120X and is diminished in the G173V mutant. (C) Active GTP-bound RHOA precipitated from podocytes expressing FLAG-ARHGDA (wild-type and mutants) using a GST-rhotekin (RHO-binding domain [RBD]) pulldown assay. Overexpression of either wild-type or mutant ARHGDA resulted in a substantial decrease in relative RHOA activity compared with mock cells. PD, pulldown. All IPs and PDs are representative of more than 3 experiments. (D) Effect on podocyte migration of wild-type ARHGDA and 2 mutants found in patients with SRNS. Migration assay was performed using the xCELLigence system (described in Methods). Overexpression of wild-type ARHGDA in podocytes inhibited serum-induced migration (green). However, the mutants G173V and R120X failed to inhibit migration (red). Error bars are shown in one direction only for clarity and indicate SDs for more than 3 independent experiments (see also Supplemental Figure 5).
(Figure 3B). In contrast, both mutants decreased the active state of RHOA (Figure 3C). This indicates that signals relayed by RAC1 and CDC42 may be more relevant to the pathogenesis of this form of SRNS than signals relayed by RHOA. In addition, we demonstrated by GST pulldown that active RAC1 is spontaneously elevated in EBV-transformed lymphoblasts from patient A1432-21 with an ARHGEDIA mutation when compared with the healthy control individual (A2238-26), while the heterozygous father (A4578-11) of an individual with an ARHGEDIA mutation (A4578-21) showed intermediate elevation (Supplemental Figure 3).

We then examined the effect of ARHGEDIA on podocyte migration using the xCELLigence system (Roche Applied Science), which monitors cell migration in real time. We found that the increase in podocyte migration, which is induced by the addition of serum, was reduced when wild-type ARHGEDIA was transfected into cultured human podocytes (Figure 3D). In contrast, the 2 ARHGEDIA mutants detected in SRNS families A1432 and A4578 failed to reduce the migratory podocyte phenotype (Figure 2D). In summary, both ARHGEDIA mutations from individuals with SRNS abrogated interaction with RHO GTPases and failed to regulate active GTP-bound RAC1 and CDC42, but not RHOA, indicating that RAC1 and CDC42 are more relevant than RHOA to the pathogenesis of this SRNS variant. The mutations resulted in a failure to regulate the migratory phenotype of cultured human podocytes (Supplemental Figure 4).

ARHGEDIA knockdown in cultured podocytes causes an increased migratory phenotype, which was reversed by RAC1 inhibitors. To test whether the effects of an ARHGEDIA mutant in podocytes result from loss of function of ARHGEDIA, we performed knockdown of ARHGEDIA in cultured human podocytes. The GST pulldown for active RAC1, CDC42, and RHOA yielded results consistent with the notion that ARHGEDIA loss of function increases the active states of RAC1 and CDC42, and RHOA yielded results consistent with the notion that ARHGEDIA loss of function mediates the migratory phenotype of cultured human podocytes (Supplemental Figure 4).

ARHGEDIA knockdown in cultured podocytes causes an increased migratory phenotype, which was reversed by RAC1 inhibitors. To test whether the effects of an ARHGEDIA mutant in podocytes result from loss of function of ARHGEDIA, we performed knockdown of ARHGEDIA in cultured human podocytes. The GST pulldown for active RAC1, CDC42, and RHOA yielded results consistent with the notion that ARHGEDIA loss of function increases the active states of RAC1 and CDC42 by 168% and 185%, respectively, but has no such effect on RHOA (Figure 4A–E, and Supplemental Figures 5 and 6).

We then examined the effect of ARHGEDIA on podocyte migration using the xCELLigence system (Roche Applied Science), which monitors cell migration in real time. We found that the increase in podocyte migration, which is induced by the addition of serum, was reduced when wild-type ARHGEDIA was transfected into cultured human podocytes (Figure 3D). In contrast, the 2 ARHGEDIA mutants detected in SRNS families A1432 and A4578 failed to reduce the migratory podocyte phenotype (Figure 2D). In summary, both ARHGEDIA mutations from individuals with SRNS abrogated interaction with RHO GTPases and failed to regulate active GTP-bound RAC1 and CDC42, but not RHOA, indicative that RAC1 and CDC42 are more relevant than RHOA to the pathogenesis of this SRNS variant. The mutations resulted in a failure to regulate the migratory phenotype of cultured human podocytes (Supplemental Figure 4).

We used our zebrafish model of arhgdia knockdown to further investigate the role of RHO GTPase inhibitors in the pathogenesis of SRNS due to loss of ARHGEDIA function. The sign of periorbital edema provided a reproducible and obvious phenotypic readout of nephrosis (Figure 5A and B). We tested RAC1 inhibitors and the mineralocorticoid inhibitor eplerenone because it has been described in Arhgdia−/− mice that RAC1 (but not RHOA) was increased and enhanced mineralocorticoid receptor–dependent (MR-dependent) signaling, while a RAC-specific small-molecule inhibitor diminished MR overactivity and renal damage, as did MR blockade by eplerenone (34).

We found that RAC1 inhibitors were partially effective in our zebrafish model in reducing edema from 70% in untreated arhgdia knockdown zebrafish to 47% for the RAC1 inhibitor–treated fish (Millipore), 47% for the RAC1 inhibitor II–treated fish (Millipore), and 54% for eplerenone–treated fish, whereas RHO inhibitors (RHO inhibitor 1, Y-27632, and fasudil) showed no effect (Figure 5C). A dose-response curve revealed that the 50% inhibitory coefficient (IC50) of the RAC1 inhibitor was 8.85 μM (Figure 5D). The protective effect of RAC1 inhibitor against arhgdia knockdown was also confirmed quantitatively by a proteinuria assay (Figure 5E). Our findings again confirm that RAC1 function is more important than RHOA in the pathogenesis caused by ARHGEDIA mutations, as we demonstrated by RAC1 activation studies (Figures 3 and 4) and as has been suggested in an Arhgdia−/− mouse model (34). In summary, we recapitulated the NS phenotype in zebrafish upon knockdown of arhgdia and revealed a mitigating effect of eplerenone and RAC1 inhibitors in the arhgdia zebrafish model.

Discussion

We demonstrate here that WER, when combined with homozygosity mapping (24), represents a valid approach for the identification of novel causative genes in rare recessive diseases. We believe this is the first study reporting ARHGEDIA mutations in humans, thereby revealing this gene’s regulatory role in RHO GTPase activity in podocytes. In summary, we found that...
Figure 4
Effects of ARHGDIA knockdown on RHO GTPase activity and podocyte migration in cultured human podocytes. (A) Active GTP-bound RAC1 and CDC42 precipitated from podocytes transfected with scrambled (Scr) or ARHGDIA siRNA using a GST-PAK1 (CRIB) pulldown assay. Ponceau red staining at the top shows the GST proteins used. Compared with control podocytes, podocytes transfected with ARHGDIA siRNA exhibited a significant increase in relative RAC1 and CDC42 (168% and 185%, respectively). The efficiency of knockdown by siRNA was confirmed by immunoblotting with an anti-ARHGDIA antibody (second to lowest panel). (B) Active GTP-bound RHOA precipitated from podocytes transfected with scrambled or ARHGDIA siRNA using a GST-rhotekin (RBD) pulldown assay. Cells transfected with scrambled control siRNA versus ARHGDIA siRNA exhibited no significant difference in relative RHOA activity. A and B represent 3 experiments each. (C–E) Quantification of RAC1 (C), CDC42 (D), and RHOA (E) in ARHGDIA-depleted cells compared with control cells. Error bars indicate the SEM for greater than 4 independent experiments. *P < 0.05; **P < 0.01; difference from proteins in control podocytes transfected with scrambled siRNA. (F) Effect of ARHGDIA knockdown on podocyte migration. Podocytes transfected with ARHGDIA siRNA exhibited more active migration compared with those transfected with scrambled siRNA. Increase in podocyte migration by ARHGDIA knockdown (red) in serum-induced podocytes was reduced by 2 different RAC1 inhibitors (green). Error bars are shown in only one direction for clarity and indicate SDs for more than 4 independent experiments.
ARHGEDIA mutations in SRNS abrogate interaction with RHO GTPases, increase active GTP-bound RAC1 and CDC42, and result in a migratory phenotypic change in podocytes.

RHO GTPases control a wide range of cellular processes, including cell adhesion, migration, and proliferation, so their activity should be tightly controlled. At any given time, only a small fraction of all RHO GTPases present in the cell are in the active GTP-bound state and are associated with membranes (40). The inactive GDP-bound pool is maintained in the cytosol by associating with RHO-specific guanine nucleotide dissociation inhibitors (RHOGDIs). There are 3 genes encoding RHOGDIs in mammals (29).

ARHGEDIA (also known as RHODGI1 or RHODGIa) is the most abundant, is ubiquitously expressed, and interacts with several RHO GTPases, including RHOA, RHOC, RAC1, RAC2, and CDC42 (29). ARHGEDIA was considered to passively lock RHO GTPases in an inactive state, but this view has now been changed by the finding that ARHGEDIA actively controls the homeostasis of RHO GTPases (41). Recently, several works using mouse genetics have shown the importance of RHO GTPase signaling in podocytes (16–18). Wang et al. showed that transgenic mice overexpressing either constitutively active or dominant-negative Rhoa in podocytes have foot process effacement and proteinuria (18). In addition, Scott et al. showed that podocyte-specific deletion of CDC42 (but not RHOA and RAC1) in mice also results in foot process effacement and proteinuria (17). The results of inactive RHOA (Rhoa knockout versus dominant-negative Rhoa transgenic mice) seem discrepant in these 2 studies, or they may suggest that the presence of dominant-negative Rhoa, rather than the absence of RHOA, causes a more severe imbalance of RHOA and RAC1/CDC42 signaling. Previously, it was demonstrated that active RAC1 (but not RHOA) is upregulated in Arhgdia–/– mice (34). In this study, we show that the ARHGEDIA mutations identified in SRNS cause the upregulation of both RAC1 and CDC42. This is congruent with the finding by Akilesh et al. that ARHGAP24 mutation was associated with FSGS and led to a podocyte phenotype very similar to that found in ARHGEDIA mutations, i.e., activation of RAC1 and CDC42 (but not RHOA), increased migratory phenotype, and proteinuria (31). In conclusion, aberrant activa-
tion of RHOA, RAC1, or CDC42 seems harmful to podocytes. However, it is not clear whether activation of RAC1 or CDC42 alone is sufficient, or whether activation of both is necessary to cause foot process effacement and proteinuria. Furthermore, it is necessary to investigate how the enhanced migratory phenotype in podocytes caused by the activation of RAC1/CDC42 ultimately leads to foot process effacement.

In this study, we show that ARHGDIA mutations caused dissociation of RHOA, RAC1, and CDC42 from ARHGDIA, and that thereafter, only RAC1 and CDC42 switched to active GTP-bound forms. RHOA was not converted to active forms and still remained in the inactive GDP-bound forms. This suggests that RHOA is regulated differently after it dissociates from ARHGDIA and other factors, and that GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs), or SMURF1 (32) may be involved.

ARHGDIA is expressed in most tissues, whereas the other 2 RHODGs (RHODGDb and RHODGDy) show tissue-specific expression (29). Considering its ubiquitous expression pattern, it is interesting that defects in ARHGDIA lead to prominent renal phenotypes in both humans and mice. Arhgdia−/− mice additionally show impaired spermatogenesis in males as well as massive proteinuria, which leads to death due to renal failure within a year (30). It is not clear whether individuals with ARHGDIA mutations also have abnormal reproductive phenotypes, however, 3 of 4 (75%) individuals from 2 independent families had neurological manifestations of homozygosity (75% individuals from 2 independent families had neurological abnormalities including intellectual disability (Table 1)). Podocytes share many cell biological characteristics with neurons. RHO GTPases also play important roles in regulating dendritic spines and branches and are vital for the maintenance and reorganization of dendritic structures in maturing neurons (42). Therefore, it is interesting to investigate whether Arhgdia−/− mice also have neurological defects or morphological abnormalities in neurons.

Our finding that RHO GTPase signaling is an important component of NS pathogenesis is emphasized by several factors: (a) The fact that single-gene recessive mutations in humans usually convey 100% penetrance and the finding that there was high penetrance in the zebrafish model of arhgdia knockdown demonstrate that ARHGDIA function is necessary to avoid the NS disease phenotype. (b) An exaggerated migratory phenotype in podocytes resulted from the activation of RAC1/CDC42 (but not RHOA) and was reversed by RAC1 inhibitors and an MR blocker. (c) Demonstration of mitigation of the zebrafish NS model by drugs that interfere with RAC1 function implicates RAC1 in the pathogenesis of SRNS via another independent route.

In summary, our findings of ARHGDIA mutation implicate the RHO small GTPase RAC1/CDC42 in the pathogenesis of human NS and permit a noninvasive, causation-based diagnosis. Furthermore, the zebrafish models we generated allow for the screening of new therapeutic options for NS.

Methods

Study participants. Informed consent was obtained from individuals worldwide with SRNS or SSNS for the use of their clinical data and blood samples. The diagnosis of NS was made by (pediatric) nephrologists based on standardized clinical and renal histological criteria (43). Renal biopsies were evaluated by renal pathologists. Clinical data were obtained using a standardized questionnaire (http://www.renalgenes.org).

Homozygosity mapping. We performed homozygosity mapping of individuals with SRNS or SSNS as established previously (24). We used the Human Mapping 250k StyI array or the Affymetrix Genome-Wide Human SNP Array 6.0. Genomic DNA samples were hybridized and scanned at the University of Michigan Core Facility using the manufacturer’s standard protocol. Nonparametric lod (NPL) scores were calculated for both affected siblings together in family A1432 as described in Hildebrandt et al. (24) using ALLEGRO and assuming first-degree cousin consanguinity of the parents, regardless of actual consanguinity status. Nonparametric NPL scores (minor allele frequency >0.2) were plotted over genetic distance across the genome, where chromosomal positions are concatenated from the p arm to the q arm (left to right) (see Figure 1A). Homozygosity peaks exceeding the empirical cutoff value of 2.0 represent possible segments of homozygosity by descent, one of which (Figure 1A, black arrowhead) harbors the homozygous disease-causing gene mutation in family A1432. We set the disease allele frequency at 0.001, and used mixed European descent marker allele frequencies.

WER. Exome enrichment was conducted following the manufacturer’s protocol for the NimbleGen SeqCap EZ Exome v2 beads (Roche NimbleGen). The kit interrogates a total of approximately 30,000 genes (~330,000 consensus-coding DNA sequence [CCDS] exons). Massively parallel sequencing was performed largely as described in Bentley et al. (44) Briefly, 3 μg of genomic DNA was fragmented by sonication using the Covaris S2 system to achieve a uniform distribution of fragments with a mean size of 300 bp. The fragmented DNA was purified using Agencourt’s AMPure XP Solid Phase Reversible Immobilization paramagnetic (SPRI) beads, followed by polishing of the DNA ends by removing the 3′ overhangs and filling in the 5′ overhangs that resulted from sonication using T4 DNA polymerase and the Klenow fragment (New England Biolabs). Following end polishing, a single A-base was added to the 3′ end of the DNA fragments using Klenow fragment (3′ to 5′ exonuclease minus). This prepares the DNA fragments for ligation to specialized adaptors that have a T-base overhang at their 3′ ends. The end- repaired DNA with a single A-base overhang was ligated to Illumina paired-end adaptors in a standard ligation reaction using T4 DNA ligase and a 2- to 4× μM final adaptor concentration, depending on the postpurification DNA yield after addition of the A-base (a 10-fold molar excess of adaptors was used in each reaction). Following ligation, the samples were purified using SPRI beads amplified by 6 cycles of PCR to maintain complexity and to avoid bias due to amplification and were then quality controlled by library size assessment using the Agilent Bioanalyzer and quantitated using PicoGreen reagent (Invitrogen).

One microgram of amplified, purified DNA (DNA library) was prepared for hybridization by adding to the DNA library Cot1 DNA and blocking oligonucleotides, desiccating the DNA completely and resuspending it in the material in NimbleGen (Roche NimbleGen) hybridization buffer. The resuspended material was denatured at 95°C prior to addition of the exome capture library bait material. The DNA library and biotin-labeled capture library were then hybridized by incubation at 47°C for 68 hours. Following hybridization, streptavidin-coated magnetic beads were used to purify the DNA/DNA hybrids formed between the capture library and sequencing library during hybridization. The purified sequencing library was amplified directly from the purification beads using 8 cycles of PCR with Pfu DNA polymerase (Invitrogen). The libraries were purified following amplification, and the library size was assessed using the Agilent Bioanalyzer. A single peak between 350 to 400 bp indicates a properly constructed and amplified library that is ready for sequencing. Final quantitation of the library was performed using the Kapa Biosystems Real-time PCR assay, and appropriate amounts were loaded onto the Illumina flow cell for sequencing by paired-end 100-nt sequencing on the Illumina HiSeq 2000.

Mutation calling. Sequence reads were mapped to the human reference genome assembly (NCBI build 36/hg18) using CLC Genomics Workbench (version 4.7.2) software (CLC bio). Mutation calling was performed with a team of geneticists and cell biologists who had knowledge of the clinical
research article

phenotypes and pedigree structure, as well as experience with homozygos-
yosity mapping and exome evaluation. Minimum length fraction of a
read to match the reference sequence was set to 90%. For SNP detection,
the minimum quality score of the central base as well as the minimum
average quality score of surrounding bases were kept at a default score of
20 and 15, respectively. Quality assessment was performed within a win-
dow of 11 bases. Only reads that uniquely aligned to the reference genome
were used for variant SNP or deletion/insertion polymorphism (DIP) call-
ing. In patients with evidence of homozygosity by descent, the threshold
for the number of reads (minor allele frequency) was set to greater than
55%. The threshold coverage for minimum valid reads (minimum variant
count), which displays the variant at a given position, was set to 2 reads.

Filtering of variants from the normal reference sequence (28). For DIPs and SNPs,
we used the following a priori criteria to restrict the high number of variants
from normal reference sequences (VRSs) (average of 53,272 for DIPs and
315,372 for SNPs) as follows (see Supplemental Table 1): (a) We retained exo-
nic variants (missense, nonsense, indels) and obligatory splice site variants
only. (b) We included only VRSs that are not in the listed in the SNP132 database
of innocuous polymorphisms. (c) We evaluated exonic changes only within
genomic regions, in which homozygosity mapping showed linkage for
both affected siblings. (d) Variants were analyzed using the BLAT program
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) on the UCSC
Human Genome Bioinformatics Browser (http://genome.ucsc.edu/) for the
presence of paralogous genes, pseudogenes, missalignments at the ends of
sequence reads, and to determine whether the variant is a known dbSNP132
with an allele frequency greater than 1% in populations of mixed European
descent. In families in whom mapping demonstrated homozygosity by
descent, we retained only homozygous variants and scrutinized all of them
in the sequence alignments within the CLC Genomic Workbench software
program for the presence of mismatches indicating potential false align-
ments or poor sequence quality. (e) Sanger sequencing was performed to
confirm the remaining variants in original DNA samples and to test for
intrafamilial segregation in a recessive mode. (f) Finally, the remaining
variants were ranked by whether mutations were truncating the conceptual
reading frame (nonsense, frameshift, and obligatory splice variants) or by
evolutionary conservation analysis of missense variants. We also used web-
based programs to predict the impact of disease candidate variants on the
encoded protein or to predict whether these variants were known disease-
causing mutations (see Supplemental Table 1).

Segregation analysis by Sanger sequencing. We applied Sanger dideoxy termi-
nator sequencing to confirm and segregate potential disease-causing vari-
ants in the respective gene(s) were analyzed by Sanger sequencing. A
touchdown PCR protocol was used as described previously (45). Sequenc-
ning was performed using a BigDye Terminator v3.1 Cycle Sequencing Kit
on an ABI 3730 XL sequencer (Applied Biosystems). Sequence traces were
analyzed using Sequencer software, version 4.8 (Gene Codes Corp.).

Web-based variant analysis. Predictions of the possible impact of an amino
acid substitution on chemical change, evolutionary conservation, and
protein function were obtained by using the following web-based pro-
grams: PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT, (Sort-
ing Intolerant from Tolerant; http://sift.jjei.org/), and Mutation Taster
(http://www.mutationtaster.org/). Genomic evolutionary rate profiling
(GERP) calculation was performed using the following: http://snp.gs.
washington.edu/SeattleSeqAnnotation137/.

Plasmids, cell culture, and transfection. A human ARHGDIA clone was pur-
chased from Open Biosystems (clone accession number BC016031.1). The
ARHGDIA mutants were generated by a PCR-based site-directed mutagen-
esis method. The immortalized human podocytes (46) were maintained
in RPMI plus GlutaMAX-I (Gibco) supplemented with 10% FBS, penicil-
lin-streptomycin (50 IU/ml and 50 μg/ml, respectively), and insulin-trans-
ferrin-selenium-X. Plasmids and siRNA were transfected into podocytes
grown at the permissive temperature of 33°C using Lipofectamine 2000
(Invitrogen). Podocytes were cultured for differentiation at 37°C for
14 days. The ARHGDIAD-specific and control scrambled siRNAs were pur-
chased from Dharmacon or Sigma-Altrich. Lymphoblasts were purified
from blood samples of individuals (A1432-21, A2338-26, and A4565-11
in Supplemental Figure 3) using Ficol-Paque PLUS (GE Healthcare)
according to the manufacturer’s instructions. The isolated lymphoblasts
were transformed by EBV and immortalized as previously described (47).

Immunoblotting, immunoprecipitation, pulldown assay, and immunofluorescence
staining. These experiments were performed as described previously (48).
The GST-PAK1 CRIB domain was purified from the BL21(DE3) E. coli
strain, and GST-rohotek RBD beads were purchased from Cyroskeleton.
Anti-FLAG, anti-Myc (Cell Signaling Technology), anti-RAC1, anti-CDC42
(BD Transduction Laboratories), anti-ARHGDA, anti-RHOA (Santa Cruz
Biotechnology), and anti-synaptopdin (American Research Products)
were purchased from the indicated commercial sources. Anti-podocalyxin
and anti-GLEPP1 antibodies were provided by Roger C. Wiggins. Anti-
PLCε1 antibody was previously described by Hinke et al. (21) and was
labeled using an APEX Alexa Fluor Labeling Kit (Invitrogen). Communuo-
precipitation was performed using EZview Red ANTI-FLAG M2 Affinity
Gel (Sigma-Altrich). The intensities of immunoblots were analyzed using
Quantity One (BioRad). Fluorescence images were obtained with a Leica
SP5X laser scanning microscope.

Podocyte migration assay. Real-time migration assays were performed using
the xCELLigence system (Roche Applied Science) in CIM-plate 16 accord-
ing to the manufacturer’s instructions. Briefly, 24 hours after transfection,
4 × 10^4 cells were plated in serum-free media in the upper chamber. The
lower chambers were filled with 10% FBS for chemotraction or with
serum-free media. The data were analyzed using RTCA software. Results
are presented as the time-versus-cell index curve.

Zebrafish studies. Zebrafish (Danio rerio) were maintained and reared as
described previously (38). Approval for zebrafish research was obtained
from the University Committee on the Use and Care of Animals (UCUCA)
of the University of Michigan. MOs were injected into the AB+ wild-type
strain for phenotype analysis of morphants and drug treatment. The pro-
teinuria assays were performed using Idfap:IVDNP-GFP transgenic fish and
a GFP ELISA kit (Cell Biolabs) as described previously (38).

Statistics. Results are presented as the means ± SEM or SD for the indi-
cated number of experiments. Statistical analysis of continuous data was
performed with a 2-tailed Student t test or a Mann-Whitney U test, as
appropriate. P < 0.05 was considered statistically significant.

Study approval. Approval for human subjects research was obtained from
the IRBs of the University of Michigan, the Université Paris Descartes, and
the University of Cologne.

Acknowledgments

The authors thank the families who contributed to this study. We thank Martin Griebel (KFH Kuratorium für Dialyse und Nie-
renentransplantation e.V., Munich, Germany) for the contribution of
clinical data. This research was supported by grants from the
NIH (DK076683 and DK086542, to F. Hildebrandt; DK46073
and DK081943, to R.C. Wiggins; DK090917, to E.A. Otto; and
DK091405, to W. Zhou). F. Hildebrandt was supported by the
NephCure Foundation. W. Zhou and C. Faul are Carl W. Gottschalk
Scholars, and H.Y. Gee is a Research Fellow of the American Society
of Nephrology (ASN). F. Hildebrandt is a Howard Hughes Medical
Institute Investigator, a Doris Duke Distinguished Clinical Scientist, and a Frederick G.L. Huetwell Professor.

Received for publication January 31, 2013, and accepted in revised form May 10, 2013.


Address correspondence to: Friedhelm Hildebrandt, Howard Hughes Medical Institute, Boston Children’s Hospital, 30 Longwood Avenue, HU319, Boston, Massachusetts 02115, USA. Phone: 617.355.6129; Fax: 617.730.0569; E-mail: Friedhelm.Hildebrandt@childrens.harvard.edu.